Percentage of participants with a positive serum IgG response to tetanus toxoid, defined as greater than or equal to (>=) 4-fold increase in anti-tetanus IgG concentrations from baseline in participants with pre-vaccination anti-tetanus IgG concentrations >= 0.1 international unit per milliliter (IU/mL); or >= 0.2 IU/mL anti-tetanus IgG concentrations in participants with pre-vaccination antitetanus IgG concentrations less than (<) 0.1 IU/mL, at Week 16 (4 weeks post-vaccination) were reported.

mITT population consisted of all randomized participants who received at least one dose of study drug and vaccine injection, had an evaluable vaccine response and did not receive any systemic rescue therapy prior to the post-vaccination vaccine response assessment.

Percentage of participants with a positive serum IgG response to tetanus toxoid, defined as >= 2-fold increase in anti-tetanus IgG concentrations from baseline in participants with pre-vaccination anti-tetanus IgG concentrations >= 0.1 IU/mL; or >= 0.2 IU/mL anti-tetanus IgG concentrations in participants with pre-vaccination Anti tetanus IgG concentrations < 0.1 IU/mL, at Week 16 (4 weeks post-vaccination) were reported.

mITT population consisted of all randomized participants who received at least one dose of study drug and vaccine injection, had an evaluable vaccine response and did not receive any systemic rescue therapy prior to the post-vaccination vaccine response assessment.

Percentage of participants with serum anti-tetanus IgG concentrations of >= 0.1 IU/mL at Week 16 were reported. The detection and characterization of antibodies to tetanus toxoid was performed using a validated immunoassay.

mITT population consisted of all randomized participants who received at least one dose of study drug and vaccine injection, had an evaluable vaccine response and did not receive any systemic rescue therapy prior to the post-vaccination vaccine response assessment.

Percentage of participants with serum anti-tetanus IgG concentrations of >= 1.0 IU/mL at Week 16 were reported. The detection and characterization of antibodies to tetanus toxoid was performed using a validated immunoassay.

mITT population consisted of all randomized participants who received at least one dose of study drug and vaccine injection, had an evaluable vaccine response and did not receive any systemic rescue therapy prior to the post-vaccination vaccine response assessment.

Percentage of participants with a positive SBA response to meningococcal serogroup C polysaccharide, defined as >= 4-fold increase in SBA reciprocal titer from baseline (using non-imputed values), at Week 16 (4 weeks postvaccination) were reported.

mITT population consisted of all randomized participants who received at least one dose of study drug and vaccine injection, had an evaluable vaccine response and did not receive any systemic rescue therapy prior to the post-vaccination vaccine response assessment. Here "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure.

Percentage of participants with a positive SBA response to MenC polysaccharide, defined as SBA reciprocal titer >= 8, at Week 16 were reported. Immune response to meningococcal vaccination was determined by measuring functional antibody responses using an SBA assay.

mITT population consisted of all randomized participants who received at least one dose of study drug and vaccine injection, had an evaluable vaccine response and did not receive any systemic rescue therapy prior to the post-vaccination vaccine response assessment. Here "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure.